Glaucoma prescribing trends in Australia and New Zealand
Article first published online: 19 APR 2006
Clinical & Experimental Ophthalmology
Volume 34, Issue 3, pages 213–218, April 2006
How to Cite
Carroll, S. C., Gaskin, B. J., Goldberg, I. and Danesh-Meyer, H. V. (2006), Glaucoma prescribing trends in Australia and New Zealand. Clinical & Experimental Ophthalmology, 34: 213–218. doi: 10.1111/j.1442-9071.2006.01196.x
- Issue published online: 19 APR 2006
- Article first published online: 19 APR 2006
- Received 23 May 2005; accepted 10 October 2005.
- glaucoma medication;
- practice pattern;
Purpose: To summarize current practice styles and patterns associated with glaucoma management in ophthalmologists of Australia and New Zealand as derived from a survey.
Method: A questionnaire was sent to all Australian and New Zealand ophthalmologists, which anonymously assessed demographic characteristics and prescribing patterns for each major class of glaucoma medication.
Results: A total of 761 questionnaires were sent with a response rate of 51%. Of respondents 14% were glaucoma subspecialists. In 69%, the first-line drug-class of choice was a prostaglandin analogue. New Zealand ophthalmologists favoured beta-blockers as their first-line agent because of cost, government restrictions and familiarity. Most respondents stated ‘hypotensive efficacy’ as the most important factor in class choice. Alpha-2-agonists, carbonic anhydrase inhibitors and miotics were considered second-line agents, because of side-effects and lack of hypotensive potency.
Conclusions: The choice of first-line agent for the treatment of glaucoma differed between Australian and New Zealand ophthalmologists, in part as the result of government restriction of prostaglandin-class drugs. Practice patterns seen in Australasia parallel the current evidence base reported in peer-reviewed literature.